Figure S6


A
Intraprostatic
Implant (PTE-82)
Days -7 0 7 14
MRI
ENZ
(20 mg/kg)
Vehicle
ENZ
Tumor Volume (mm3)
Days post treatment
B
Subcutaneous
Implant (TRAMP-C2)
Days -14 0 7 14
Caliper
ENZ
(10 mg/kg)
Vehicle
ENZ
Tumor Volume (mm3)
Days post treatment
C
IgG (n=14)
αCSF-1 (n=13)
IgG + Lupron (n=15)
αCSF-1 + Lupron (n=14)
Tumor Volume (mm3)
Days post implantation
*
***
0.21
D
IgG
IgG + Lupron
αCSF-1
αCSF-1 +
Lupron
E
CD3
Expression (%)
αCSF-1
Lupron
IgG
200 micron
F
CD31
Expression (%)
αCSF-1
Lupron
G
***
***
% of CD45+
IgG
Lupron
αCSF-1
αCSF-1 + Lupron
CD11b+F480+
Macrophage
CD11b+Ly6C+
Monocyte
CD11b+Ly6G+
Neutrophil
CD19+MHCII+
B cell
CD3+CD4+
T cell
CD3+CD8+
T cell

Supplemental Figure 6, Related to Figure 6. A) PTE-82 tumor cells were implanted orthotopically into the prostates of C57 mice, which were then treated with enzalutamide as indicated. Tumor volumes were measured by MRI on the indicated days. Data are shown as mean ± SEM, pooled from two independent experiments. B) TRAMP-C2 tumor cells were implanted subcutaneously into flanks of C57 mice, which were then treated with enzalutamide as indicated. Tumor volumes were measured by caliper on the indicated days. Data are shown as mean ± SEM from a single experiment. C) PTE-82 tumor cells were implanted orthotopically into prostates of C57 mice, which were then treated with Lupron depot and/or αCSF-1 as indicated. Tumor volumes were measured by MRI on the indicated days. n=13-15 mice per group, data are shown as mean ± SEM, pooled from two independent experiments. Significance determined by two-way ANOVA. D) Representative T2-weighted MRI images of the mice from A. E) Quantification of percent pixel positivity for CD3 in tumor tissue from mice treated with Lupron depot and/or αCSF-1. Representative images from formalin-fixed, paraffin-embedded prostate tissue from the IgG treated group is shown. F) Quantification of percent pixel positivity for CD31 in tumor tissue from mice treated with Lupron depot and/or αCSF-1. G) Immune repertoire of orthotopic PTE-82 tumors following treatment with Lupron depot and/or αCSF-1. 17 days post implant, tumors were excised and single cell suspensions were processed for flow cytometry.